Shots:

• Akebia receives $25M up front in place of the previous milestone of $25M, following the US FDA approval of vadadustat & holds 66% of the profit of pre-specified costs. Under the commercial supply agreement, Vifor will contribute $40M working investment to partially fund Akebia's costs of manufacturing vadadustat with an equity purchase of $20M
• Vifor gets an exclusive license to sell vadadustat to FMCNA and other entities in the US for anemia due to CKD. The company is expected to launch Vadadustat with an expected PDUFA date is Mar 29, 2022
• Under the collaboration with Otsuka, Akebia has retained rights to commercialize vadadustat in non-dialysis dependent markets & dialysis organizations

 Ref: PR Newswire | Image: Trading View